Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 8/20 | 0.86 |
| ▸ | KMT2A | Q03164 | 17/20 | 0.84 |
| ▸ | MEN1 | O00255 | 14/20 | 0.84 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.84 |
| ▸ | RECQL | P46063 | 2/20 | 0.84 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.81 |
| ▸ | HPGD | P15428 | 1/20 | 0.75 |
| ▸ | POLB | P06746 | 5/20 | 0.72 |
| ▸ | CRHBP | P24387 | 5/20 | 0.72 |
| ▸ | CRHR2 | Q13324 | 5/20 | 0.72 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.70 |
| ▸ | GAA | P10253 | 1/20 | 0.70 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6785292 | 1.00 | MAPT (0.86) | MAPTKMT2AMEN1MAPK1RECQL | |
| SCHEMBL6779900 | 0.86 | KMT2A (1.00) | MAPTKMT2AMEN1MAPK1RECQL | |
| SCHEMBL6779898 | 0.86 | KMT2A (1.00) | MAPTKMT2AMEN1MAPK1RECQL | |
| SCHEMBL6906446 | 0.83 | KMT2A (0.86) | MAPTKMT2AMEN1MAPK1RECQL | |
| SCHEMBL6906444 | 0.83 | KMT2A (0.86) | MAPTKMT2AMEN1MAPK1RECQL | |
| SCHEMBL6898863 | 0.82 | KMT2A (1.00) | MAPTKMT2AMEN1MAPK1RECQL | |
| SCHEMBL6898866 | 0.82 | KMT2A (1.00) | MAPTKMT2AMEN1MAPK1RECQL | |
| SCHEMBL6785408 | 0.81 | KMT2A (1.00) | MAPTKMT2AMEN1MAPK1RECQL | |
| SCHEMBL6786118 | 0.81 | KMT2A (0.81) | MAPTKMT2AMEN1MAPK1RECQL | |
| SCHEMBL6786122 | 0.81 | KMT2A (0.81) | MAPTKMT2AMEN1MAPK1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6727267-B2 | COMPOUND FOR USE IN THE TREATMENT OF VIRAL DISEASES | TULARIK INC. | 2004-04-27 | — | — | US | disclosed |
| US-20020142290-A1 | Compound for use in the treatment of viral diseases | TULARIK INC. (US) | 2002-10-03 | — | — | US | disclosed |
| WO-2001077091-A2 | NS5B HCV POLYMERASE INHIBITORS | TULARIK INC. (US) | 2001-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020142290-A1 | Compound for use in the treatment of viral diseases | POLRMT, RNASE1, POLI | MAPT 1867/4885KMT2A 2870/4885MEN1 4349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.